These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36915890)

  • 1. Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database.
    Tan Z; Chen Z; Yao G; Mumin MA; Wang Y; Zhu J; Xu Q; Chen W; Liang H; Wang Z; Deng Q; Luo J; Wei J; Cao J
    Transl Androl Urol; 2023 Feb; 12(2):330-346. PubMed ID: 36915890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
    Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
    Lane G; Risk M; Fan Y; Krishna S; Konety B
    BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis.
    Jue JS; Koru-Sengul T; Miao F; Velásquez MC; Sávio LF; Alameddine M; Kroeger ZA; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Minerva Urol Nephrol; 2021 Oct; 73(5):572-580. PubMed ID: 32026665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
    Sawasdee A; Tanthanuch M; Bejrananda T
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
    Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting.
    Kwon T; Jeong IG; Lee J; Lee C; You D; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):169-76. PubMed ID: 25119986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    Cha EK; Sfakianos JP; Sukhu R; Yee AM; Sjoberg DD; Bochner BH
    BJU Int; 2018 Oct; 122(4):627-632. PubMed ID: 29633530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Moschini M; Poletajew S; Chorbińska J; Necchi A; Montorsi F; Briganti A; Sanchez-Salas R; Shariat SF; Palou J; Babjuk M; Teoh JY; Soria F; Pradere B; Ornaghi PI; Pawlak A; Dembowski J; Zdrojowy R
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33567656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis.
    Kool R; Dragomir A; Kulkarni GS; Marcq G; Breau RH; Kim M; Busca I; Abdi H; Dawidek M; Uy M; Fervaha G; Cury FL; Alimohamed N; Izawa J; Jeldres C; Rendon R; Shayegan B; Siemens R; Black PC; Kassouf W
    Eur Urol Oncol; 2024 Dec; 7(6):1350-1357. PubMed ID: 38326142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy.
    Ploussard G; Pradere B; Beauval JB; Chevreau C; Almeras C; Suc E; Gautier JR; Laurenty AP; Roumiguié M; Loison G; Tollon C; Mourey L; Salin A; Xylinas E; Pouessel D
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32585894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database.
    Darwish C; Sparks A; Amdur R; Reddy A; Whalen M
    Urology; 2020 Dec; 146():168-176. PubMed ID: 32866509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    Soria F; Black PC; Fairey AS; Cookson MS; Yu EY; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Daneshmand S; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Shariat SF; Gontero P
    BJU Int; 2021 Jul; 128(1):79-87. PubMed ID: 33152179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013.
    Chalfant V; Blute ML; Silberstein P
    Asian J Urol; 2023 Jan; 10(1):9-18. PubMed ID: 36721688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.